cas 53857-57-1|| where to buy 5-bromo-1H-indazole

Nom du produit:5-bromo-1H-indazole

IUPAC Name:5-bromo-1H-indazole

Unité d'emballage	Stock disponible	Prix($)
CM100735-100g	in stock	Ŵƀ
CM100735-500g	in stock	ǊƦƀ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 53857-57-1 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:53857-57-1; Formule moléculaire:C7H5BrN2; Point de fusion:-; Code SMILES:BrC1=CC2=C(NN=C2)C=C1; Densité:1.77 g/cm3

: Numéro de catalogue:CM100735; Poids moléculaire:197.04; Point d'ébullition:333.8°C at 760 mmHg; N° Mdl:MFCD00839493; Stockage:Pretect from light and store in a dry and close container at room temperature

: Indazoles; Indazoles are a class of organic heterocyclic compounds, also known as 1,2-diazaindene and benzopyrazole. Indazole is a good bioisomer of phenol, which is more lipophilic than phenol and less prone to phase I and II metabolism. Indazole derivatives have a wide range of biological activities, and it has been confirmed that indazole compounds have anti-tumor, analgesic, anti-inflammatory and other drug activities. Anticancer is the most important application field of indazole drugs. Renal cell carcinoma, solid tumor, nausea and vomiting caused by chemotherapy and leukemia are the main indications of this structural backbone drug.

: Orforglipron; Obesity is becoming an increasingly serious public health problem globally, plaguing millions of people and significantly increasing their risk of chronic diseases such as diabetes and heart disease. In recent years, with the approval of new weight loss drugs such as Wegovy (Semaglutide) and Mounjaro (Tirzepatide), people's attention to this field has once again heated up, spawning an upsurge in the research and development of new treatments. There are currently nearly 70 obesity treatments in the research and development stage. Eli Lilly's Orforglipron is the world's first oral small molecule GLP-1RA to start Phase III clinical trials.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.